Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis.

Thierry LandreGaetan Des GuetzKader ChouahniaVirginie Fossey-DiazStéphane Culine

Published in: Drugs & aging (2021)

ICIs appear to be effective in patients aged ≥ 75 years. However, the survival benefit is mainly observed in first-line treatment and remains unclear in the second-line setting.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
advanced cancer
palliative care
peritoneal dialysis
patient reported outcomes